Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 11/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.44 |
| ▸ | PIP5K1C | O60331 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | LIPC | P11150 | 5/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072602 | 0.87 | PIK3CA (0.46) | PIK3CGPIK3CA | |
| SCHEMBL10072307 | 0.87 | ROCK2 (0.41) | ROCK2 | |
| SCHEMBL10044687 | 0.85 | PI4KA (0.40) | PI4KAPI4KBPIK3CDPIK3CGPIP5K1C | |
| SCHEMBL10044786 | 0.85 | ROCK2 (0.38) | ROCK2ALDH1A1 | |
| SCHEMBL10044653 | 0.82 | JAK3 (0.40) | ROCK2 | |
| SCHEMBL10044668 | 0.82 | PI4KA (0.47) | PI4KAPI4KBPIK3CDPIK3CGPIP5K1C | |
| SCHEMBL10072356 | 0.82 | ROCK2 (0.38) | ROCK2ALDH1A1 | |
| SCHEMBL10072308 | 0.80 | ATM (0.36) | ROCK2ALDH1A1 | |
| SCHEMBL10072529 | 0.78 | CLK4 (0.47) | ALDH1A1 | |
| SCHEMBL13305844 | 0.78 | CLK4 (0.48) | ALDH1A1TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PI4KA 101/4885PI4KB 141/4885PIK3CD 99/4885 |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PI4KA 101/4885PI4KB 141/4885PIK3CD 99/4885 |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PI4KA 101/4885PI4KB 141/4885PIK3CD 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.